Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

BACKGROUND: Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a single-patient case report. We present data from the primary analysis of a phase 2 study of daratumumab monotherapy in relapse...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Hematol Oncol
Autors principals: Huang, Huiqiang, Zhu, Jun, Yao, Ming, Kim, Tae Min, Yoon, Dok Hyun, Cho, Seok-Goo, Eom, Hyeon Seok, Lim, Soon Thye, Yeh, Su-peng, Song, Yuqin, Kwong, Yok Lam, Kim, Jin Seok, Jin, Jie, Shi, Yuankai, Kim, HyeJin, Qing, Min, Zhou, Tianyuan, Gao, Grace, Dong, Zongqi, Qi, Ming, Kim, Won Seog
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7885403/
https://ncbi.nlm.nih.gov/pubmed/33588922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-01020-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars